2026 Crowdfunding Campaign
CROWFUNDING ROUND IS OPEN
Help 2.8 million dialysis patients regain their lives.
The groundbreaking Neokidney™ portable hemodialysis device will be launched in 2027. This device will give back autonomy and quality of live to many kidney patients all over the world. Nextkidney will be the first to make portable hemodialysis available to patients. Next up : Through Invesdor, you'll now have one last chance to invest in the Dutch company Nextkidney BV before its commercial launch.
- From 275 Euros, you can take part

WHY NEXTKIDNEY
Dialysis to better fit in normal life.
For 2.8 million people living with kidney failure, dialysis is not only a lifesaving treatment. It is a rhythm that defines everyday life : hospital appointments, travel limits, schedules, low energy levels and constant planning around care.
Neokidney is a portable home hemodialysis device in the process of CE marking. It combines compact patented technology (10kg) with a much lower need for dialysis fluid (5ltr.) and a unique plug and play concept as its needs no special infrastructure at all. With the Neokidney system finally, treatment adapts to the patient instead of the other way around.
WHY NOW
A decade of progress, step by step.
Since 2014, every year has brought Neokidney closer to patients : engineering, testing, manufacturing, recent clinical trial results and currently regulatory progress towards CE approval and FDA clearance. What remains is certification and the preparation for market introduction.
RAISED SINCE THE LAST CROWFUNDING ROUND
€40.1M
Series B, EIC Accelerator and European Investment Bank
CLINICAL TREATMENTS SUCCESSFULLY PERFORMED
500+
By dialysis nurses in medical centres in NL, BE and FR
PATIENTS IN EU CLINICAL TRIALS
29
Studies running at UMC's in Utrecht, Leiden, Brussels and Caen
Insurer backing, technical standards, NEN Innovation Award, Series B2014 to 2022
Foundation
Key step toward CE markingJUN 2023
ISO 13485 certified
In a Series B equity roundDEC 2023
€22.6M raised
First in human tests in Singapore and FranceJUL 2024
First human trials
Pilot line brings sorbent production in house, lowering cost and supplier dependenceJUL 2024
€3M government grant
ALCER patient award for renal care innovationNOV 2024
Patient Innovation Award
€2.5 million EIC non-dilutive funding and a contitional 15 million equity investmentJUL 2025
European Innovation Award
In 4 European clinical centres start to treat 25 patients in 500 treatmentsJAN 2026
EU clinical trials start
Treatments performed successfully and ready to progress towards in-home studySEP 2026
500+ treatments
CE and FDA pathways, scaling production capacity, market introductionWHAT COMES NEXT
Certification and launch
NEW
Prof. Dr. med. Dieter Bach joins as Chief Medical Officer
Strengthening the clinical leadership team.
Internationally recognized nephrologist and home hemodialysis expert with over 30 years of experience in kidney care and dialysis innovation. Previously served as Chairmen of KfH, Germany’s largest kidney care and dialysis organization.
As CMO of Nextkidney, he leads the clinical and medical strategy behind the Neokidney, helping ensure the device delivers safe, effective, and patient-centered treatment while supporting its adoption in clinical practice.

THREEFOLD VALUE
Why this matters, on three levels.
01 Quality of life
More freedom for patients while enabling health gain by more frequent and friendlier treatment.
More control over the week, mobility with treatment fitting easy into regular daily live of people who depend on dialysis. The Neokidney device is designed for ease of use to enable patients to take their treatment whenever, wherever they need.
02 Healthcare system
Less pressure on care
Reduced healthcare costs and pressure on scarce medical staff and dialysis capacity.
03 Investors
Participation on equal terms
This investment round is now open and crowd investors can take part through Invesdor on the same terms as the current professional investors. It is the last opportunity to invest before the commercial launch.
SOCIAL PROOF
Healthcare insurers, Nephrologists and Patients believe in the Neokidney
Prof. Dr. Marcel Levi
Kidney patient, Janneke Bresser
SUPPORTED BY AND IN COLLABORATION WITH









